Trends in Oncology Clinical Trials Launched Before and During the COVID-19 Pandemic

Elizabeth B Lamont; Sheila S Diamond; Ron G Katriel; Lisa L Ensign; Jingshu Liu; Emelly Rusli; G Caleb Alexander

doi:10.1001/jamanetworkopen.2020.36353

Trends in Oncology Clinical Trials Launched Before and During the COVID-19 Pandemic

JAMA Netw Open. 2021 Jan 4;4(1):e2036353. doi: 10.1001/jamanetworkopen.2020.36353.

Authors

Elizabeth B Lamont¹, Sheila S Diamond², Ron G Katriel², Lisa L Ensign², Jingshu Liu², Emelly Rusli¹, G Caleb Alexander^{3

4

5}

Affiliations

¹ Acorn AI, by Medidata, a Dassault Systèmes Company, Boston, Massachusetts.
² Acorn AI, by Medidata, a Dassault Systèmes Company, New York, New York.
³ Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
⁵ Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

Abstract

This cohort study evaluates the association of the coronavirus disease 2019 (COVID-19) pandemic with clinical research and development for cancer by studying the initiation of oncology clinical trials over time.

Publication types

Observational Study

MeSH terms

COVID-19*
Clinical Trials as Topic / statistics & numerical data*
Humans
Logistic Models
Medical Oncology / trends*
Neoplasms*
SARS-CoV-2
Time Factors*